Generic Drugs Market is expected to display an exponential growth by 2027

Our Bureau

According to a new report published by UnivDatos Markets Insights the Generic Drugs Market is expected to grow at a CAGR of over 7% from 2021-2027. The analysis has been segmented into Type (Simple, Super, Biosimilar); Application (Neurological Diseases, Cardiological Diseases, Metabolic Diseases, Infectious Diseases, Orthopedic Diseases, Genitourinary/Hormonal Diseases, Respiratory […]

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Our Bureau

Concept Medical announces the successful completion of the TRANSFORM 1 RCT (TReAtmeNt of Small coronary vessels: Randomized controlled trial FOR MagicTouch Sirolimus Coated Balloon). The Randomized Controlled Trial (RCT) was conceptualized with the aim of understanding how the treatment indications and applications of Drug Coated Balloon (DCB) in coronary artery […]

Could a Phytochemical derived from Vegetables like Broccoli be the Answer to Antibiotic Resistant Pathogens

Our Bureau

Antibiotic-resistant bacterial pathogens are increasingly playing a role in rising illness and preventing wound healing, especially in hospitals. While more and more pathogens have developed biofilms that protect them from being eradicated by antibiotics, fewer classes of antibiotics are being developed. Researchers from Ben-Gurion University of the Negev decided to […]

Cognota receives US FDA approval for BP monitor device

Our Bureau

Leading healthtech company Cognota Healthcare on Monday announced that the United States Food and Drug Administration (US FDA) has approved the company’s blood pressure monitor device- ‘COGNOHEALTH Blood Pressure Monitor’, marking the successful foray of the company into the medical devices segment.The regulatory approval is a significant milestone for Cognota […]

DCGI approved AstraZeneca’s Lynparza as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer

Our Bureau

AstraZeneca India, a leading science-led biopharmaceutical company, today announced that it has received a Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer, who have previously been treated […]

Subscribe Now